Literature DB >> 1425981

Doxorubicin: an antagonist of muscarinic receptors in guinea pig heart.

K Temma1, T Akera, A Chugun, M Ohashi, M Yabuki, H Kondo.   

Abstract

While studying the mechanisms of doxorubicin-induced cardiotoxicity, we observed that doxorubicin inhibited the negative inotropic effect of acetylcholine in isolated heart muscle preparations. We therefore examined the effects of doxorubicin on muscarinic acetylcholine receptors. In left atrial muscle preparations isolated from guinea pig heart and stimulated at 2 Hz at 30 degrees C, doxorubicin caused a parallel right-ward shift of the dose-response curves for the negative inotropic effects of acetylcholine. The inhibitory action was reversed by an additional incubation in the absence of doxorubicin. Doxorubicin reversed the carbachol-induced inhibition of developed tension: a high concentration of doxorubicin brought the force back to its original strength. Doxorubicin inhibited specific [3H]quinuclidinyl benzilate (QNB) binding to membrane preparations obtained from ventricular muscle of guinea pig hearts. The pA2 value for doxorubicin obtained in the inotropic study corresponded to the IC50 value for doxorubicin observed in the [3H]QNB binding assay. These results indicate that doxorubicin acts as a weak competitive antagonist on muscarinic acetylcholine receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425981     DOI: 10.1016/0014-2999(92)90012-s

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Detrimental effects of chemotherapy on human coronary microvascular function.

Authors:  Shelby N Hader; Natalya Zinkevich; Laura E Norwood Toro; Alison J Kriegel; Amanda Kong; Julie K Freed; David D Gutterman; Andreas M Beyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-09       Impact factor: 4.733

2.  The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial.

Authors:  Paweł Stachowiak; Andrzej Wojtarowicz; Marta Milchert-Leszczyńska; Krzysztof Safranow; Michał Falco; Robert Kaliszczak; Zdzisława Kornacewicz-Jach
Journal:  Oncotarget       Date:  2017-09-27

Review 3.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.